INTRODUCTION AND OBJECTIVES: Male urethral stricture disease (USD) is a relatively common condition often requiring multiple endoscopic and open procedures as treatment. Repeat urethral catheterization is a risk factor for USD likely resulting from focal urethral ischemia leading to scar formation but this process is not well understood. We sought to better understand the impact of urethral expansion on tissue microperfusion using a rabbit model. METHODS: 12 NZ white male rabbits were anesthetized and their urethras wereserially expanded using pulmonary CRE balloons (Boston Scientific), which expand to 24/27/30/33 Fr. Concentration and velocity of red blood cells are recorded using a 4 Fr endoscopic sideviewing laser Doppler flowmetry (LDF) probe (Moor Instruments). To assess the impact of expansion time on microperfusion, the balloon was expanded to 30 Fr and LDF measurements were continuously recorded for 30 minutes. Rabbits were euthanized at 0 or 1 week and their urethras harvested and stained for hematoxylin and eosin (H&E) to study the acute and chronic effects of urethral expansion.
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RESULTS: Increasing urethral expansion was shown to have an inverse linear relationship tissue microperfusion. Tissue microperfusion was decreased by 74% at 33 Fr expansion compared to 24 Fr (34.30 vs. 107.9 perfusion units (PU), p <0.05). Over time, tissue perfusion increased slightly from nadir of 42.7 PU to peak of 52.4 PU before stabilizing at an expansion on 30 Fr. However, perfusion did not reach normal values at any time period tested. On H&E staining, there was evidence of acute inflammation at week 0 that was no longer present after 1 week. We did not see any evidence of scar formation over this short time period.
CONCLUSIONS: Increasing urethral expansion diameter and duration leads to decreased tissue microperfusion. There is evidence of acute inflammation initially that resolves after 1 week although no scar formation is noted over this time period. Future studies will assess for scar formation with longer expansion times and further time points. 
INTRODUCTION AND OBJECTIVES:
The United States is facing an opioid epidemic. Surgeons play a critical role, with the incidence of chronic opioid use following surgical procedures impacting up to 10% of patients. Limited evidence exists to guide procedure-specific opioid prescribing best practices and non-opioid based care pathways. We sought to evaluate postoperative opioid requirements and evaluate efficacy of a standardized perioperative pain management pathway for men undergoing anterior urethroplasty.
METHODS: Between August 2017 and October 2018, we prospectively evaluated consecutive men undergoing outpatient urethroplasty by a single surgeon. Standardized perioperative pain pathways were implemented based on urethroplasty location (penile vs. bulbar) and on need for buccal mucosa graft (Figure 1) . Postoperative opioid usage, amount of unused opioid, pain scores (Likert 0 best to 10 worst), and patient satisfaction with pain management (Likert 6 very satisfied to 1 very dissatisfied) were evaluated.
RESULTS: Data was obtained in 46 of 57 consecutive outpatient urethroplasties at a median 14 days after surgery. Median age was 52 years (range 18-77) and postoperative 72 hour pain score was 3 (range 0-8). A total of 7 (15%) patients reported narcotic use within 7 days before surgery. The median number of 5 mg oxycodone tablets used after urethroplasty was 3.5 (range 0-42); 36 of 46 (78%) men used 5 tablets or less. Excess narcotic was prescribed to 38 of 46 (83%) with a median 14 unused tablets (range 5-27) per patient. Postoperative narcotic usage did not differ by age, urethroplasty location, or use of buccal mucosa graft, but was significantly greater among patients that reported preoperative narcotic usage (median 15 vs. 3 tabs; p[0.0008). Men without preoperative narcotic usage rarely required > 5 tablets relative to those using narcotics preoperatively (13% vs. 71%; p[0.003). Overall, 93% (n[43) reported satisfaction (Likert score 5 or 6) with the postoperative pain management strategy.
CONCLUSIONS: In combination with the defined non-opioid care pathway, 5 tablets of 5 mg oxycodone provides satisfactory pain control following anterior urethroplasty in patients without preoperative opioid use, while limiting overprescribing.
